Added to YB: 2024-07-19
Pitch date: 2024-07-12
MRUS [bullish]
Merus N.V.
+68.37%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands.
Market Cap
$7.3B
Pitch Price
$57.57
Price Target
N/A
Dividend
N/A
EV/EBITDA
-17.68
P/E
-17.90
EV/Sales
114.35
Sector
Biotechnology
Category
growth
Show full summary:
TimesSquare U.S. Small Cap Growth Strategy New Position: Merus N.V.
MRUS: Clinical-stage immune-oncology biotech. Pipeline targets solid tumors with bispecific antibodies. New addition to portfolio. Focus on innovative cancer treatments.
Read full article (1 min)